2Segaert S,Van Cutsem E.Clinical signs,pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors[J].Ann Oncol.2005;16(9):1425-1433.
4Mendelsohn J,Baselga J.Epidermal growth factor receptor targeting in cancer[J].Semin Oncol,2006,33(4):369-385.
5Arteaga CL.The epidermal growth factor receptor:From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia[J].J Clin Oncol,2001,19(suppl 18):32S-40S.
6Fox LP.Nail toxicity associated with epidermal growth factor receptor inhibitor therapy[J].J Am Acad Dermatol,2007,56(3):460-465.
7Lenz HJ.Anti-EGFR mechanism of action:antitumor effect and underlying cause of adverse events[J].Oncology,2006,20(5suppl 2):5-13.
9Giaccone G,Herbst RS,Manegold C,et al.Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer:a phase Ⅲ trial-INTACT1[J].J Clin Oncol,2004,22(5):777-784.
10Johnson JR,Cohen M,Sridhara R,et al.Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen[J].Clin Cancer Res,2005,11(18):6414-6421.
